Human SPARC Alexa Fluor® 594-conjugated Antibody Summary
Accession # P09486
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
SPARC, an acronym for “secreted protein, acidic and rich in cysteine”, is also known as osteonectin or BM-40 (1-5). It is the founding member of a family of secreted matricellular proteins with similar domain structure. The 286 amino acid (aa), 43 kDa protein contains an N-terminal acidic region that binds calcium, a follistatin domain that contains Kazal-like sequences, and a C-terminal extracellular calcium (EC) binding domain with two EF-hand motifs (1-5). Crystal structure modeling shows that residues implicated in cell binding, inhibition of cell spreading, and disassembly of focal adhesions cluster on one face of SPARC, while a collagen binding epitope and an N-glycosylation site are opposite this face (6). SPARC is produced by fibroblasts, capillary endothelial cells, platelets and macrophages, especially in areas of tissue morphogenesis and remodeling (3, 7). SPARC shows context-specific effects, but generally inhibits adhesion, spreading and proliferation, and promotes collagen matrix formation (3-5). For endothelial cells, SPARC disrupts focal adhesions and binds and sequesters PDGF and VEGF (3-5). SPARC is abundantly expressed in bone, where it promotes osteoblast differentiation and inhibits adipogenesis (5, 8). SPARC is potentially cleaved by metalloproteinases, producing an angiogenic peptide that includes the copper-binding sequence KGHK (7). Paradoxically, SPARC is highly expressed in many tumor types undergoing an endothelial to mesenchymal transition; its expression, however, mainly decreases the likelihood of metastasis and confers sensitivity to chemotherapy and radiation (4, 9-11). Stabilin-1, which is expressed on alternately activated macrophages, is the first SPARC receptor to be identified. It binds the SPARC EC domain and mediates endocytosis for degradation (12). Mature human SPARC shows 92%, 92%, 97%, 99%, 96% and 85% aa identity with mouse, rat, canine, bovine, porcine and chick SPARC, respectively.
- Lankat-Buttgereit, B. et al. (1988) FEBS Lett. 236:352.
- Sweetwyne, M. T. et al. (2004) J. Histochem. Cytochem. 52:723.
- Sage, H. et al. (1989) J. Cell Biol. 109:341.
- Framson, P. E. and E. H. Sage (2004) J. Cell. Biochem. 92:679.
- Alford, A. I. and K. D. Hankenson (2006) Bone 38:749.
- Hohenester, E et al. (1997) EMBO J. 16:3778.
- Sage, E. H. et al. (2003) J. Biol. Chem. 278:37849.
- Delany, A. M. et al. (2003) Endocrinology 144:2588.
- Robert, G. et al. (2006) Cancer Res. 66:7516.
- Koblinski, J. E. et al. (2005) Cancer Res. 65:7370.
- Tai, I. T. et al. (2005) J. Clin. Invest. 115:1492.
- Kzhyshkowska, J. et al. (2006) J. Immunol. 176:5825.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human SPARC Alexa Fluor® 594-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human SPARC Alexa Fluor® 594-conjugated Antibody and earn rewards!
Have you used Human SPARC Alexa Fluor® 594-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image